This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Media
-
Race reaches agreement with TrueMed for Bisantrene sales in Israel
Race Oncology is very pleased to announce that it has executed a Named Patient Program (NPP) distribution and sales agreement in Israel with TrueMed Ltd. According to Race, TrueMed is a pharmaceutical distributor with experience in driving NPPs in Israel. Under the agreement, TrueMed will have the exclusive right to sell and distribute RAC’s chemotherapy…
-
Race appoints BioSynergy to pursue Bisantrene licensing
Race Oncology is pleased to announce it has executed a services agreement with BioSynergy Partners LLC (BioSynergy) to pursue licensing and other deals for Bisantrene (the ‘Agreement’). BioSynergy is a transaction consulting business owned by Dr John Cullity, a non-executive director of RAC. Under the Agreement, potential transactions include any sale, license, partnership, collaborative venture…
-
The devastating impact of AML and why we need hope
A Perth family tells the story of their son’s battle with Acute Myeloid Leukaemia. When Kai got sick, they searched the world for answers.
-
Race Oncology produces first batch of Bisantrene for sale
Race Oncology Limited (RAC) is pleased to announce it has produced its first good manufacturing practice (GMP) batch of cancer drug Bisantrene. The first batch will be enough to treat up to sixty patients, with a further four batches scheduled to be produced before the end of September. “Race Oncology has achieved one of the most…
-
Race appoints US consultant to drive partnering, investment, clinical funding
Race Oncology is pleased to announce that it has executed an agreement with Mr Tom Lee to assist Race with partnering and funding opportunities in the US, with a focus on Houston, Texas. Mr Lee is well-connected to the MD Anderson Cancer Center and other institutions, opinion-leaders and investors in Texas. Under the initial 12-month agreement,…
-
Bisantrene receives ‘Rare Paediatric Disease’ designation from FDA
Race Oncology is pleased to announce that it has received a letter from the FDA advising that Bisantrene has been granted Rare Paediatric Disease (RPD) designation for the treatment of childhood Acute Myeloid Leukaemia (AML). The RPD designation means Bisantrene has the opportunity to be awarded a Priority Review Voucher (PRV) from the FDA at the time of…
-
Long-term survival case report of patients treated with Bisantrene Combination Therapy
The poster below details the long-term survival case report of two paediatric relapsed or refractory Acute Myeloid Leukemia patients treated with Bisantrene Combination Therapy.
-
Bisantrene granted unlicensed medicine approval in UK
Race Oncology is pleased to announce that approval has been received from the Medicines and Healthcare products Regulatory Agency (MHRA) for importation and distribution of Bisantrene as an unlicensed medicine in the UK. The letter from the MHRA was received by Race’s distribution partner, Durbin PLC, on 20 June 2018. Under MHRA regulations, the supply…